A single Mito-Ru MOF treatment downregulates NEAT1 and inhibits the production of ROS, thereby reducing Freund’s adjuvant (CFA)-induced temporomandibular joint disorders (TMD). Here, NEAT1 is linked to temporomandibular joint disorder.